In 2015, more than 8 million people died from various kinds of cancers all over the world.Although traditional chemotherapeutic drugs are widely used in clinic, more than 50％ of cancers are significantly resistant to traditional chemotherapeutic drugs.Tubulin targeting agents have been confirmed to be effective anti-cancer drugs in clinic.However, some anti-microtubule agents developed resistance after long-term use, such as paclitaxel and vinblastine.In recent years, it is reported that tubulin modulators targeting on the colchicine-binding site are extremely effective against multi-drug resistant cancer cells.In this article, different anti-microtubule agents targeting multi-drug resistant cancers are reviewed.

Radiopharmaceuticals are the cornerstone of molecular imaging and precision medicine, which play a huge role in the diagnosis and treatment of malignant tumors, central nervous system diseases, cardiovascular and other diseases. On the basis of summarizing the advantages of radiopharmaceuticals and analyzing the development status at home and abroad, this article specifically introduces the general process of radiopharmaceutical research and development, and analyzes the key points of research and development. Finally, the future development of radiopharmaceuticals is prospected, with a view to providing reference for practitioners in fields related to the creation of new radiopharmaceuticals and accelerating the radiopharmaceutical development in China.

Objective To synthesize and investigate cytotoxicity of an indole-chalcone derivative FC58. Methods The target compound was synthesized through the Aldol condensation with 1-(3,4,5-trimethoxyphenyl)ethan-1-one and 1H-indole-3-carbaldehyde. The Cell Titer-Blue method was used to determine in vitro cytotoxicity. The cell cycle experiment was performed to analyze the action characteristics of FC58. Results FC58 exhibited high cytotoxicity against various leukemia cells and resulted in G2/M phase arrest. It showed stronger drug resistant index than traditional tubulin inhibitors such as paclitaxel, vinblastine and doxorubicin. Conclusion FC58 represents a promising lead compound for multi-drug resistant leukemia.